Raymond James Reiterates Global Blood Therapeutics (GBT) at Market Perform, Concerns Over Oxbryta’s Long Term Potential Remain
Tweet Send to a Friend
Raymond James analyst Danielle Brill reiterated a Market Perform rating on Global Blood Therapeutics (NASDAQ: GBT), following the company's most ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
